Diagnostic gastroenterology

Olympus Supports New Recommendation to Begin Colorectal Cancer Screenings at Age 45

Retrieved on: 
Thursday, July 1, 2021
Medicine, Clinical medicine, Health, Diagnostic gastroenterology, Colorectal cancer, Cancer screening, Medical terminology, Prevention, Colonoscopy, United States Preventive Services Task Force, Cancer, Screening

CENTER VALLEY, Pa., July 1, 2021 /PRNewswire/ -- Today, Olympus announced its support of the new recommendation issued by the United States Preventive Services Task Force (USPSTF) to begin colorectal cancer screenings for all individuals beginning at age 45.

Key Points: 
  • CENTER VALLEY, Pa., July 1, 2021 /PRNewswire/ -- Today, Olympus announced its support of the new recommendation issued by the United States Preventive Services Task Force (USPSTF) to begin colorectal cancer screenings for all individuals beginning at age 45.
  • Age is one of the most prominent risk factors of colorectal cancer, with 94% of cases found in those who are 45 years or older.
  • "This cause is meaningful to Olympus as the pioneering manufacturer of endoscopic devices used to detect and treat colorectal cancer, and it's very meaningful to me personally as I lost my father to colorectal cancer.
  • Research shows that this new age recommendation is important for all, but crucial for Black individuals because early onset colorectal cancer is much more common.6
    To learn more about colorectal cancer and screenings, visit Colonoscopy Today .

Motus GI to Present at the Ladenburg Thalmann Healthcare Conference

Retrieved on: 
Tuesday, June 29, 2021
Microsoft, Software, Operating systems, Communication, Forward-looking statement, Diagnostic gastroenterology, Endoscopy, Motus, LinkedIn, Twitter

Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions.

Key Points: 
  • Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions.
  • For more information, visit www.motusgi.com and connect with the Company on Twitter , LinkedIn and Facebook .
  • Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof.
  • The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Ambu Supports FDA’s Recommendations on the Use of Single-use Bronchoscopes

Retrieved on: 
Friday, June 25, 2021
Biotechnology, General Health, FDA, Other Health, Health, Medicine, Clinical medicine, Health, Diagnostic gastroenterology, Endoscopy, Ambu, Treatment and management of COVID-19, Bronchoscopy, COVID-19, Axess Vision Technology

The FDA recommends that healthcare providers consider using single-use bronchoscopes where there is increased risk of spreading infection, or no support for immediate reprocessing available.

Key Points: 
  • The FDA recommends that healthcare providers consider using single-use bronchoscopes where there is increased risk of spreading infection, or no support for immediate reprocessing available.
  • This latest update follows recent recommendations from the American Association for Bronchology and Interventional Pulmonology (AABIP) on treating COVID-19 patients.
  • Ambu believes that any patient that enters the OR or ICU should not be exposed to further risk of infection.
  • In 2020, more than 1 million Ambu single-use endoscopes were used around the world, making Ambu the worlds largest supplier of single-use endoscopes.

EvoEndo® Raises $10.1 Million to Make Unsedated Transnasal Endoscopy a Reality for Patients and Physicians

Retrieved on: 
Tuesday, June 8, 2021
Hospitals, Health, Medical devices, Diagnostic gastroenterology, Endoscopy, Food and Drug Administration, Medicine, Health care, Health

EvoEndo Inc., (EvoEndo or the Company) a preclinical medical device company developing systems for unsedated Transnasal Endoscopy (TNE), announced it has secured $10.1M in equity financing.

Key Points: 
  • EvoEndo Inc., (EvoEndo or the Company) a preclinical medical device company developing systems for unsedated Transnasal Endoscopy (TNE), announced it has secured $10.1M in equity financing.
  • EvoEndo was co-founded in 2017 by Dr. Joel Friedlander, a pediatric gastroenterologist, and the interdisciplinary aerodigestive medicine team at Childrens Hospital of Colorado.
  • EvoEndos mission is to make endoscopies safer for patients by eliminating the need for general anesthesia while reducing the complexity and cost of endoscopy for physicians and hospitals.
  • EvoEndos system is currently pending U.S. FDA 510(k) clearance and is not available for sale in the United States.

Motus GI Announces Publication of Pure-Vu® System Clinical Data in Peer-Reviewed Journal BMC Gastroenterology

Retrieved on: 
Thursday, June 3, 2021
Clinical medicine, Medicine, Cancer screening, Large intestine, Colonoscopy, Diagnostic gastroenterology, Endoscopy, Forward-looking statement

Among the important findings that the Company continues to emphasize since the data from the REDUCE study were first announced is the Pure-Vu systems 97% clinical success rate.

Key Points: 
  • Among the important findings that the Company continues to emphasize since the data from the REDUCE study were first announced is the Pure-Vu systems 97% clinical success rate.
  • Evaluation of the data from our REDUCE study continues to support our belief that the Pure-Vu System can significantly improve bowel preparation quality in hospitalized subjects undergoing colonoscopy.
  • The article covers clinical data from the REDUCE study.
  • Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof.

Esophageal Cancer 2021 Study - Presented by G7 Countries Including the US, France, Spain, Italy, UK and Japan - ResearchAndMarkets.com

Retrieved on: 
Monday, May 31, 2021
Health, Oncology, Medical specialties, Gastroenterology, Clinical medicine, Esophageal cancer, Gastrointestinal cancer, Epidemiology of cancer, Esophageal, Cancer, Diagnostic gastroenterology, Dysphagia, Esophageal pH monitoring

The research report, Global Esophageal Cancer Epidemiology and Patient Flow Analysis - 2021, provides Esophageal Cancer epidemiology, demographics, and patient flow.

Key Points: 
  • The research report, Global Esophageal Cancer Epidemiology and Patient Flow Analysis - 2021, provides Esophageal Cancer epidemiology, demographics, and patient flow.
  • The research provides population data to characterize Esophageal Cancer patients, history of the disease at the population level (Esophageal Cancer prevalence, Esophageal Cancer incidence) and at the clinical level (from diagnosis to treated patients).
  • Demographics: Esophageal Cancer patients by age group, gender
    The data from this research will help executives:
    Establish basis for Esophageal Cancer market sizing, assessing market potential, and developing drug forecast models
    Identify Esophageal Cancer patients segments through age groups, gender, and disease sub-types
    Evaluate Esophageal Cancer market opportunities, identify target patient population
    1.
  • US Esophageal Cancer Patient Flow, 2020 - 2035
    4.

NEC's AI Supports Doctors to Detect Neoplasia in Barrett's Esophagus during Endoscopic Procedures

Retrieved on: 
Friday, May 28, 2021
Medical specialties, Gastroenterology, Anatomy, Abdomen, Digestive system, Organs, Barrett's esophagus, Diagnostic gastroenterology, Esophageal cancer, Endoscopy, Esophagus, Stomach

TOKYO, May 28, 2021 - (JCN Newswire) - NEC Corporation (NEC; TSE: 6701) today announced the development of an AI technology for supporting doctors to detect neoplasia in Barrett's esophagus during endoscopic procedures.

Key Points: 
  • TOKYO, May 28, 2021 - (JCN Newswire) - NEC Corporation (NEC; TSE: 6701) today announced the development of an AI technology for supporting doctors to detect neoplasia in Barrett's esophagus during endoscopic procedures.
  • This software is connected to endoscopy processors and automatically notifies users of potential Barrett's neoplasia from images captured during endoscopic procedures.
  • Barrett's esophagus is a pre-cancerous condition in which the inner lining of the esophagus is replaced by a lining that resembles that of the stomach.
  • Patients with Barrett's esophagus have 30-40 fold higher risk of developing cancer of the esophagus as compared to the normal population (4).

NEC’s AI Supports Doctors to Detect Neoplasia in Barrett’s Esophagus During Endoscopic Procedures

Retrieved on: 
Friday, May 28, 2021
Oncology, Health, Medical devices, Technology, Photography, Audio, Video, Software, Medical specialties, Gastroenterology, Anatomy, Abdomen, Digestive system, Organs, Barrett's esophagus, Diagnostic gastroenterology, Esophageal cancer, Esophagus, Endoscopy, Stomach cancer

NEC Corporation (NEC; TOKYO: 6701) today announced the development of an AI technology for supporting doctors to detect neoplasia in Barretts esophagus during endoscopic procedures.

Key Points: 
  • NEC Corporation (NEC; TOKYO: 6701) today announced the development of an AI technology for supporting doctors to detect neoplasia in Barretts esophagus during endoscopic procedures.
  • (Graphic: Business Wire)
    This software is connected to endoscopy processors and automatically notifies users of potential Barretts neoplasia from images captured during endoscopic procedures.
  • Barretts esophagus is a pre-cancerous condition in which the inner lining of the esophagus is replaced by a lining that resembles that of the stomach.
  • Patients with Barretts esophagus have 30-40 fold higher risk of developing cancer of the esophagus as compared to the normal population (*3).

Global Disposable Endoscopes Industry (2020 to 2027) - Key Market Trends and Drivers - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 26, 2021
Other Manufacturing, Manufacturing, Diagnostic gastroenterology, Endoscopy, Compound annual growth rate

The "Disposable Endoscopes - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Disposable Endoscopes - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Bronchoscopy, one of the segments analyzed in the report, is projected to record a 19.7% CAGR and reach US$1.1 Billion by the end of the analysis period.
  • The U.S. Market is Estimated at $269.6 Million, While China is Forecast to Grow at 24.1% CAGR
    The Disposable Endoscopes market in the U.S. is estimated at US$269.6 Million in the year 2020.
  • In the global Arthroscopy segment, USA, Canada, Japan, China and Europe will drive the 15.1% CAGR estimated for this segment.

EndoFresh Obtains FDA 510(k) Clearance for Its Groundbreaking Disposable Digestive Endoscopy System

Retrieved on: 
Monday, May 24, 2021
Clinical medicine, Endoscopy, Medicine, Medical specialties, Diagnostic gastroenterology, Endoscope, Medical device

EndoFresh Disposable Digestive Endoscopy System features a camera system with innovative all-in-one design, disposable upper GI endoscope and disposable colonoscope, which are used together with the medical display and other peripheral devices to allow physicians to visualize, diagnose and operate gastrointestinal endoscopy.

Key Points: 
  • EndoFresh Disposable Digestive Endoscopy System features a camera system with innovative all-in-one design, disposable upper GI endoscope and disposable colonoscope, which are used together with the medical display and other peripheral devices to allow physicians to visualize, diagnose and operate gastrointestinal endoscopy.
  • According to the agency statement, the problems identified with reprocessed urological endoscopes and duodenoscopes may apply to similar devices.
  • Since the global flexible endoscope market blossoming for safety and effectiveness, many manufacturers have engaged in the R&D of disposable endoscope.
  • Established in 2014, EndoFresh is a Chinese high-tech medical device manufacturing enterprise engaged in R&D and manufacture of high-end disposable digestive endoscopes.